Zobrazeno 1 - 10
of 18 481
pro vyhledávání: ''
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Daniel Moj, Nicola Ammer, Babette Aicher, Jan-Georg Wojtyniak, Thorsten Lehr, Michael Teifel, Herbert Sindermann, Hannah Britz, Nina Hanke
Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors. The aim of this study was to establish a physi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c5e9a18956370d7aca5ee1061fd910
Autor:
Ashish Panigrahi, Constantine S. Tam, Piers Blombery, Xiangting Chen, John F. Seymour, Dennis A. Carney, Andrew H. Wei, Thomas E Lew, Mary Ann Anderson, Andrew W. Roberts, Ella R. Thompson, David C. S. Huang, Tamia Nguyen, David Westerman, Michael A. Dengler, Victor S Lin, Sasanka M. Handunnetti, Jerry M. Adams
Publikováno v:
Blood. 139:1198-1207
The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). As BCL2 is an important determinant of survival of both myeloid progenitor and B cells, we investigated whether cl
Autor:
Julie Means-Powell, Luis Del Valle, Vandana G. Abramson, Claudia Sorrentino, Melinda Sanders, Ingrid A. Mayer, Debra A. Tonetti, Roohi Ismail-Khan, Samarpan Majumder, Richard M Lush, Lucio Miele
Publikováno v:
Clin Breast Cancer
Preclinical studies have demonstrated a complex cross-talk between Notch and estrogen signaling in ERα-positive breast cancer. Gamma-secretase inhibitors (GSIs) are investigational agents that block the cleavage and activation of Notch receptors. In
Publikováno v:
Future Oncology
Introduction: The objective of this study was to evaluate the clinical and laboratory outcomes of solid cancer patients who were reinfected with COVID-19. Methods: Patients who were tested negative on the Coronavirus disease 2019 (COVID-19) PCR test
Autor:
Christopher J. Patterson, Lian Xu, Tanya Siddiqi, Maria Luisa Guerrera, Shayna Sarosiek, Zachary R. Hunter, Andrew R. Branagan, Xia Liu, Carly Leventoff, Catherine A Flynn, Ranjana H. Advani, Kirsten Meid, Nicholas Tsakmaklis, Maria Demos, Matthew S. Davids, Guang Yang, Amanda Kofides, Timothy P White, Manit Munshi, Steven P. Treon, Jorge J. Castillo, Richard R. Furman, John N. Allan
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(1)
PURPOSE BCL2 is overexpressed and confers prosurvival signaling in malignant lymphoplasmacytic cells in Waldenström macroglobulinemia (WM). Venetoclax is a potent BCL2 antagonist and triggers in vitro apoptosis of WM cells. The activity of venetocla
Autor:
Duo Li, Shunliang Xu, Zhang Yangting, Lei Chen, Shengjie Pei, QiuZhen Wang, Xin He, Qianqian Shen, Hongzhuan Yu
Publikováno v:
Journal of Alzheimer's Disease. 85:573-585
Background: 5-Hydroxymethylcytosine (5hmC) is an epigenetic DNA modification that is highly abundant in nervous system. It has been reported that 5hmC is significant associated with Alzheimer’s disease (AD). Changes in 5hmC signatures can be detect
Autor:
Stefanie D. Krens, Wim van Boxtel, Carla M.L. van Herpen, Sasja F. Mulder, Frank G A Jansman, Maike J. M. Uijen, Ingrid M.E. Desar, Nielka P. van Erp
Publikováno v:
International Journal of Cancer, 150, 308-316
International Journal of Cancer, 150, 2, pp. 308-316
International Journal of Cancer, 150(2), 308-316. Wiley
International Journal of Cancer, 150, 2, pp. 308-316
International Journal of Cancer, 150(2), 308-316. Wiley
Contains fulltext : 249093.pdf (Publisher’s version ) (Open Access) Cabozantinib is registered in fixed 60 mg dose. However, 46% to 62% of patients in the registration studies needed a dose reduction due to toxicity. Improved clinical efficacy has
Autor:
Guofan Xu, Lei Feng, Hun Ju Lee, Michelle Avellaneda, Preetesh Jain, Linghua Wang, Luis Fayad, Omar Moghrabi, L. Jeffrey Medeiros, Cezar Iliescu, Nathan Fowler, Shuangtao Zhao, Yang Liu, Selvi Thirumurthi, Michael L. Wang, Chi Young Ok, Maria Badillo, Lucy Navsaria, Graciela M. Nogueras González, David Santos, Christopher R. Flowers, Francisco Vega, Guilin Tang, Holly Hill, Rashmi Kanagal-Shamanna, Fredrick B. Hagemeister, Yixin Yao
Publikováno v:
J Clin Oncol
PURPOSE Most patients with mantle cell lymphoma (MCL) are older. In this study, we investigated the efficacy and safety of a chemotherapy-free combination with ibrutinib and rituximab (IR) in previously untreated older patients with MCL (age ≥ 65 y
Publikováno v:
Nitric Oxide. 118:17-25
AIMS Patients with type 2 diabetes mellitus (T2DM) have reduced vasodilatory responses during exercise partially attributable to low nitric oxide (NO) levels. Low NO contributes to greater α-adrenergic mediated vasoconstriction in contracting skelet